Latest Headlines

Latest Headlines

Prosensa picks up $7M to speed up DMD development

Prosensa, one of a handful of biotechs racing to develop treatments for Duchenne muscular dystrophy, has secured $7 million from a nonprofit to accelerate its R&D efforts.

Prosensa gets an FDA green light for its once-failed DMD drug

After a late-stage failure and a kiss-off from partner GlaxoSmithKline, Prosensa and its innovative treatment for Duchenne muscular dystrophy seemed to be on a downward slope. But now, after a series of "positive" meetings with the FDA, the company says it plans to submit its breakthrough-designated drug for approval this year, taking advantage of the agency's accelerated pathway.

Upbeat review of PhII DMD trial earns Prosensa a big boost to shares

After the markets closed last night, Prosensa issued an upbeat self-assessment of its 48-week extension data from a Phase II study of its lead drug drisapersen for Duchenne muscular dystrophy.

Prosensa heralds new hope for once-failed muscular dystrophy drug

Prosensa's Duchenne muscular dystrophy treatment endured a Phase III setback that led partner GlaxoSmithKline to head for the exit, but the Dutch biotech is back with a new analysis of drisapersen's data that could spell a path forward, sending its shares up 25%.

GSK dumps a failed muscular dystrophy drug back in Prosensa's lap

GlaxoSmithKline has shut the door on its hopes in Duchenne muscular dystrophy, handing back rare-disease drug drisapersen to Prosensa, its former partner.

Danish biotech Egalet pitches $69M IPO on Nasdaq

A Danish biotech company with a foothold in the U.S. is making a bid to cash in on the big IPO boom on Nasdaq. Egalet, which has been developing abuse-resistant opioid pain pills, has outlined plans to raise $69 million from an initial offering. That cash would primarily be used to develop a couple of late-stage programs nearing the clinic.

Muscular dystrophy drug from GlaxoSmithKline, Prosensa fails PhIII

GlaxoSmithKline and Prosensa today conceded defeat in the Phase III study for drisapersen, one of two closely-watched therapies for Duchenne muscular dystrophy which had been vying for the lead in the field. Investigators reported that the therapy failed to significantly improve walking distance in patients.

UPDATED: Prosensa harvests $78M as biotech IPOs continue to sizzle

Prosensa picked the right day to price its IPO. The Dutch biotech rang up the offering at $13 a share, at the top of the range, raising $78 million after bumping the number of shares on offer to 6 million. The stock will trade on Nasdaq as "RNA."

Glaxo grabs coveted breakthrough drug status for muscular dystrophy drug

GlaxoSmithKline has landed the FDA's coveted breakthrough therapy designation for drisapersen, a late-stage treatment for Duchenne muscular dystrophy that is engaged in a fierce clinical race with Sarepta's closely watched DMD drug eteplirsen.

Ex-Genzyme CEO Termeer returns to his roots at biotech Prosensa

The former Genzyme CEO and chairman has joined the biotech Prosensa as a strategic adviser, bringing his experience in building Genzyme into a world leader in rare diseases.